Navigation Links
BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
Date:11/19/2013

JERUSALEM, Nov. 19, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today the publication of results showing that BL-8040 (formerly known as BKT-140) enables the efficient mobilization of stem cells from the bone marrow into the peripheral blood, thus facilitating autologous stem cell transplantation in multiple myeloma patients. The research was published in the journal, Clinical Cancer Research.

(Logo:  http://photos.prnewswire.com/prnh/20130730/630769)

High-dose chemotherapy followed by autologous stem cell transplantation has emerged as an established treatment modality for a variety of hematologic malignancies, including multiple myeloma, non-Hodgkin lymphoma and Hodgkin lymphoma. Stem cells are mobilized from the bone marrow using granulocyte colony-stimulating factor (G-CSF), harvested from the peripheral blood by apheresis, and re-infused to the patient after chemotherapy. This type of treatment often replaces the more traditional use of bone marrow transplantation, because the stem cells are easier to collect and the treatment allows for a quicker recovery time and fewer complications.

In patients that do not respond well enough to G-CSF (up to 20% in multiple myeloma), treatment is often augmented by Plerixafor, a drug that inhibits CXCR4, a chemokine receptor that is important in hematopoietic stem cell homing to the bone marrow. However, even after the dual treatment, the mobilization of a sufficient number of stem cells remains a difficult objective in a sizeable proportion of patients.

BL-8040 is a novel, potent and selective inhibitor o
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Reports Third Quarter 2013 Financial Results
2. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
3. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
4. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
5. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
6. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
7. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
8. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
9. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
10. BioLineRx to Present at 15th International Celiac Disease Symposium
11. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ ... its CytoSorb® extracorporeal cytokine adsorber to reduce deadly ... the receipt of $385,642, net of transaction costs, ... the Technology Business Tax Certificate Transfer Program sponsored ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... WASHINGTON, Oct. 12 Boston,Scientific Corporation (NYSE: ... nearly 7,500 patients from its TAXUS ARRIVE 1 ... performance of the TAXUS(R) Express2(TM),Paclitaxel-Eluting Coronary Stent System ... that the TAXUS Stent reduced clinical,restenosis in patients ...
... 10 Boston Scientific,Corporation (NYSE: BSX ... Company,s major,events and press announcements at the ... Therapeutics (TCT),scientific symposium, which runs from October ... Boston Scientific will be announcing a wide ...
Cached Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce ... ever created for kids with cancer. The Chemo Duck App, available ... filled with enjoyable games to help children of all ages living ... helps to keep kids entertained, educated and at ease while waiting ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... study finds some benefit from calcium channel blockers , , ... channel blockers to control their high blood pressure may ... long-term use of the drugs also might cut the ... findings are far from definitive and not yet ready ...
... MarketResearch.com, a leading online,provider of syndicated market ... the global market for specialty medical beds ... Inc., Making available to global business ... Therapeutic Surfaces Worldwide,MarketResearch.com provides a comprehensive market ...
... Employer Services, a,leading software and services provider of ... Service solutions,announces the launch of its new HSA ... up with an experienced and trusted,partner, Evolution Benefits, ... 2007 to provide this new offering. Their combined,solution ...
... patients receiving aggressive drug therapy to cut blood sugar ... large North American trial designed to aggressively lower the ... heart disease has been halted because of an unexpected ... , Federal health officials announced Wednesday that 257 ...
... DALLAS and FORT WORTH, Texas, Feb. 6 ... to help accelerate,advancements in the treatment of cancer, ... Practice Benchmark, an initiative to assist community,oncology practices ... will be open to all community-based oncology,practices nationally. ...
... MEDW ) announced today the return of Mr. ... announced that long term director,Joseph Delario, resigned from the ... age 64, has more than 30 years senior level ... He is the,founder and currently the Chief Technology Architect ...
Cached Medicine News:Health News:Blood Pressure Drugs Might Prevent Parkinson's 2Health News:Blood Pressure Drugs Might Prevent Parkinson's 3Health News:MarketResearch.com Distributes Key Findings on Global Specialty Medical Beds and Therapeutic Surfaces Market 2Health News:Mangrove Announces Health Savings Account (HSA) and Health Reimbursement Account (HRA) Product Launches 2Health News:Deaths Halt Part of Large Diabetes Trial 2Health News:Deaths Halt Part of Large Diabetes Trial 3Health News:Deaths Halt Part of Large Diabetes Trial 4Health News:Oncology Metrics Launches the National Practice Benchmark: One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operational and Financial Performance 2Health News:Philip Coelho Joins Mediware Board 2Health News:Philip Coelho Joins Mediware Board 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: